Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs

被引:28
作者
Wyns, H. [1 ]
Meyer, E. [1 ]
Plessers, E. [1 ]
Watteyn, A. [1 ]
De Baere, S. [1 ]
De Backer, P. [1 ]
Croubels, S. [1 ]
机构
[1] Univ Ghent, Fac Vet Med, Dept Pharmacol Toxicol & Biochem, B-9820 Merelbeke, Belgium
关键词
Gamithromycin; Pharmacokinetics; Pig; Absolute bioavailability; Subcutaneous; LUNG-TISSUE CONCENTRATIONS; TULATHROMYCIN; AZITHROMYCIN; TILMICOSIN; MODULATION; MACROLIDES; CYTOKINES; TYLOSIN; PLASMA;
D O I
10.1016/j.rvsc.2013.11.012
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The aim of this study was to investigate the pharmacokinetic properties of gamithromycin in pigs after an intravenous (i.v.) or subcutaneous (s.c.) bolus injection of 6 mg/kg body weight. The plasma concentrations of gamithromycin were determined using a validated high-performance liquid chromatography-tandem mass spectrometry method, and the pharmacokinetics were noncompartmentally analysed. Following i.v. administration, the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(inf)) and the mean elimination half-life (t(1/2 lambda z)) were 3.67 +/- 0.75 mu g.h/mL and 16.03 h, respectively. The volume of distribution at steady state (V-ss) and the plasma clearance were 31.03 +/- 6.68 L/kg and 1.69 +/- 0.33 L/h.kg, respectively. The mean residence time (MRTinf) was 18.84 +/- 4.94 h. Gamithromycin administered subcutaneously to pigs demonstrated a rapid and complete absorption, with a mean maximal plasma concentration (C-max) of 0.41 +/- 0.090 mu g/ml at 0.63 +/- 0.21 h and a high absolute bioavailability of 118%. None of the reported pharmacokinetic variables significantly differed between both administration routes. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:160 / 163
页数:4
相关论文
共 20 条
  • [1] Pharmacokinetics and lung tissue concentrations of tulathromycin in swine
    Benchaoui, HA
    Nowakowski, M
    Sherington, J
    Rowan, TG
    Sunderland, SJ
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (04) : 203 - 210
  • [2] Buret AG, 2010, CAN J VET RES, V74, P1
  • [3] Tilmicosin and tylosin have anti-inflammatory properties via modulation of COX-2 and iNOS gene expression and production of cytokines in LPS-induced macrophages and monocytes
    Cao, Xing-Yuan
    Dong, Mei
    Shen, Jian-Zhong
    Wu, Bei-Bei
    Wu, Cong-Ming
    Du, Xiang-Dang
    Wang, Zhuo
    Qi, Yi-Tao
    Li, Bing-Yu
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 (05) : 431 - 438
  • [4] EMA, 2011, EUR AG EV MED PROD
  • [5] European Medicines Agency [EMA], 2008, EUR AG EV MED PROD
  • [6] Susceptibility testing of tulathromycin: Interpretative breakpoints and susceptibility of field isolates
    Godinho, K. S.
    [J]. VETERINARY MICROBIOLOGY, 2008, 129 (3-4) : 426 - 432
  • [7] Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity
    Huang, R. A.
    Letendre, L. T.
    Banav, N.
    Fischer, J.
    Somerville, B.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2010, 33 (03) : 227 - 237
  • [8] Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156
  • [9] Azalides from azithromycin to new azalide derivatives
    Mutak, Stjepan
    [J]. JOURNAL OF ANTIBIOTICS, 2007, 60 (02) : 85 - 122
  • [10] Pharmacokinetics and pharmacodynamics of newer macrolides
    Nightingale, CH
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (04) : 438 - 443